Hepion Pharmaceuticals Faces Nasdaq Delisting Warning
Ticker: CTRVP · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1583771
| Field | Detail |
|---|---|
| Company | Hepion Pharmaceuticals, Inc. (CTRVP) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $1.00, $1.00 m |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, nasdaq
TL;DR
Nasdaq says Hepion's stock price is too low, giving them 6 months to fix it or get booted.
AI Summary
Hepion Pharmaceuticals, Inc. announced on September 3, 2024, that it received a notification from The Nasdaq Stock Market indicating a failure to meet the minimum bid price requirement for continued listing. The company has 180 calendar days, until March 2, 2025, to regain compliance.
Why It Matters
This filing signals potential delisting from Nasdaq, which could significantly impact the company's liquidity, investor confidence, and ability to raise capital.
Risk Assessment
Risk Level: high — The company is at high risk of being delisted from Nasdaq due to failing to meet the minimum bid price requirement.
Key Numbers
- 180 — Days to regain compliance (The company has this many days to meet Nasdaq's minimum bid price requirement.)
Key Players & Entities
- Hepion Pharmaceuticals, Inc. (company) — Registrant
- The Nasdaq Stock Market (company) — Listing Exchange
- September 3, 2024 (date) — Notification Date
- March 2, 2025 (date) — Compliance Deadline
FAQ
What specific Nasdaq listing rule has Hepion Pharmaceuticals failed to meet?
Hepion Pharmaceuticals failed to meet the minimum bid price requirement for continued listing on The Nasdaq Stock Market.
What is the deadline for Hepion Pharmaceuticals to regain compliance with Nasdaq's listing rules?
The company has until March 2, 2025, to regain compliance.
What is the consequence if Hepion Pharmaceuticals does not regain compliance?
If Hepion Pharmaceuticals does not regain compliance, it risks delisting from The Nasdaq Stock Market.
What was the date of the notification from Nasdaq?
The notification from Nasdaq was received on September 3, 2024.
Has Hepion Pharmaceuticals previously been subject to a similar notification?
The filing does not provide information on previous notifications regarding listing requirements.
Filing Stats: 667 words · 3 min read · ~2 pages · Grade level 13.9 · Accepted 2024-09-05 06:15:40
Key Financial Figures
- $0.0001 — h registered: Common Stock, par value $0.0001 per share HEPA The Nasdaq Stock Mar
- $1.00 — ness days, had closed below the minimum $1.00 per share and, as a result, the Company
- $1.00 m — e Company is not in compliance with the $1.00 minimum bid price requirement for the con
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-24-035076.txt ( ) — 211KB
- hepa-20240903.xsd (EX-101.SCH) — 3KB
- hepa-20240903_lab.xml (EX-101.LAB) — 34KB
- hepa-20240903_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 5, 2024 Hepion Pharmaceuticals, Inc. By: /s/ John Brancaccio John Brancaccio Interim Chief Executive Officer and Interim Chief Financial Officer - 3 -